A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
404
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Boehringer Ingelheim